ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Non-GAAP gross margin (% of revenue) by Year
Non-GAAP gross margin (% of revenue) (%)
Eli Lilly Non-GAAP gross margin (% of revenue): 83.8% in FY2025, up 1.3 pts from a year earlier.
Latest, FY2025
83.8%
Period ended Dec 31, 2025
Change on a year earlier
+1.3 pts
82.5% in FY2024
History
4 years
Since FY2022
Sources
3
Documents cited below
Where the FY2025 figure comes from
“|| Gross Margin as a percent of revenue - Non-GAAP (2) | 83.2 | % | 83.2 | % | 83.8 | % | 82.5 | % 1.Excludes amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties.”
Source: Earnings Release (Form 8-K FY2025Q4 EX-99.1) (filed 2026-02-04) ↗
Reported in Form 8-K Non-GAAP Reconciliation Schedules.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Non-GAAP gross margin (% of revenue) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 83.8% | +1.3 pts | Earnings Release (Form 8-K FY2025Q4 EX-99.1) (filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | 82.5% | +1.8 pts | Earnings Release (Form 8-K FY2024Q4 EX-99.1) (filed 2025-02-06) ↗ |
| FY2023 | Dec 31, 2023 | 80.7% | +1.9 pts | Earnings Release (Form 8-K FY2023Q4 EX-99.1) (filed 2024-02-06) ↗ |
| FY2022 | Dec 31, 2022 | 78.8% | – | Earnings Release (Form 8-K FY2023Q4 EX-99.1) (filed 2024-02-06) ↗ |
Cite this data
StockData. (2026). Eli Lilly Non-GAAP gross margin (% of revenue) (%), annual FY2022–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/gm-nongaap-pct
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.